Protocol for the Examination of Resection Specimens From Pediatric Patients With Rhabdomyosarcoma

Version: 4.1.1.1
Protocol Posting Date: September 2022

The use of this protocol is recommended for clinical care purposes but is not required for accreditation purposes.

This protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated marginal resection, wide local resection, radical resection, amputation, or other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhabdomyosarcoma</td>
<td>Includes pediatric patients with all rhabdomyosarcoma variants and ectomesenchymoma</td>
</tr>
</tbody>
</table>

The following should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
<td>(consider Rhabdomyosarcoma Biopsy protocol)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult Rhabdomyosarcoma*</td>
<td>(consider using soft tissue protocol)</td>
</tr>
</tbody>
</table>

*Rhabdomyosarcoma in adults may be treated differently than pediatric rhabdomyosarcoma and use of the AJCC TNM staging system remains appropriate for adult patients.

Authors
Jessica L. Davis, MD*; Michael A. Arnold, MD, PhD; Archana Shenoy, MD; Lea Surrey, MD; Aaron R. Weiss, DO; Erin R. Rudzinski, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author.

Accreditation Requirements
The use of this case summary is recommended for clinical care purposes but is not required for accreditation purposes. The core and conditional data elements are routinely reported. Non-core data elements are indicated with a plus sign (+) to allow for reporting information that may be of clinical value.
Summary of Changes
v 4.1.1.1

- The 'Expert Consultation' question was made optional
- Added Explanatory ‘Note A’ and associated with the ‘Expert Consultation’ question
Reporting Template
Protocol Posting Date: September 2022
Select a single response unless otherwise indicated.

CASE SUMMARY: (RHABDOMYOSARCOMA AND RELATED NEOPLASMS: Resection)

EXPERT CONSULTATION

+Expert Consultation (Note A)
___ Pending - Completion of this CAP Cancer Protocol is awaiting expert consultation
___ Completed - This CAP Cancer Protocol or some elements have been performed following expert consultation
___ Not applicable

CLINICAL

Preoperative Treatment (select all that apply)
___ No known preoperative therapy
___ Chemotherapy given
___ Radiation therapy given
___ Preoperative therapy given, type not specified
___ Not specified

SPECIMEN (Note B)

Procedure (Note C)
___ Marginal resection
___ Wide local resection
___ Radical resection
___ Amputation (specify type): _________________
___ Other (specify): _________________
___ Not specified

TUMOR

Tumor Site
___ Bile duct
___ Bladder / prostate
___ Cranial / parameningeal
___ Extremity
___ Genitourinary (excluding bladder / prostate)
___ Head and neck (excluding parameningeal)
___ Orbit
___ Other(s) (includes trunk, retroperitoneum, etc.) (specify): _________________
___ Not specified
Tumor Size
___ Greatest dimension in Centimeters (cm): ________________ cm
  +Additional Dimension in Centimeters (cm): ____ x ____ cm
___ Cannot be determined (explain): ________________

Histologic Type (Note D)
___ Embryonal
___ Alveolar
___ Spindle cell / sclerosing
___ Ectomesenchymoma
___ Rhabdomyosarcoma, not otherwise specified (NOS): ________________
___ Other (specify): ________________
  +Histologic Type Comment: ________________

Anaplasia (Note E)
___ Not identified
___ Focal (single or few scattered anaplastic cells)
___ Diffuse (clusters or sheets of anaplastic cells)
___ Cannot be determined: ________________

+Treatment Effect (Note F)
___ Not identified
___ Present
  +Percentage of Treatment Effect
    ___ Specify percentage: ________________ %
    ___ Other (specify): ________________
    ___ Cannot be determined: ________________
  +Percentage of Therapy-Induced Cytodifferentiation
    ___ Specify percentage: ________________ %
    ___ Other (specify): ________________
    ___ Cannot be determined: ________________
    ___ Cannot be determined: ________________
    ___ Not applicable

+Tumor Comment: ________________

MARGINS

Margin Status (Note G)
___ All margins negative for tumor

Distance from Tumor to Closest Margin
Specify in Centimeters (cm)
___ Exact distance: ________________ cm
___ Greater than: ________________ cm
    ___ At least: ________________ cm
___ Less than: ________________ cm
___ Less than 1 cm
___ Other (specify): __________________
___ Cannot be determined: __________________

**Closest Margin(s) to Tumor**
___ Specify closest margin(s): __________________
___ Cannot be determined (explain): __________________
___ Tumor present at margin

**Margin(s) Involved by Tumor**
___ Specify involved margin(s): __________________
___ Cannot be determined (explain): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________
___ Not applicable

+Margin Comment: __________________

**REGIONAL LYMPH NODES**

**Regional Lymph Node Status**
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
    ___ All regional lymph nodes negative for tumor
    ___ Tumor present in regional lymph node(s)

**Number of Lymph Nodes with Tumor**
___ Exact number (specify): __________________
___ At least (specify): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

**Number of Lymph Nodes Examined**
___ Exact number (specify): __________________
___ At least (specify): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

+Regional Lymph Node Comment: __________________

**DISTANT METASTASIS**

**Distant Site(s) Involved, if applicable**
___ Not applicable
___ Specify site(s): __________________
___ Cannot be determined: __________________
PATHOLOGIC STAGE (Note H)

The Intergroup Rhabdomyosarcoma Study Postsurgical Clinical Grouping System (Note H)

Grouping is based on pretreatment tumor characteristics. Clinical information required to definitively assign stage group (e.g., gross residual disease or distant metastatic disease) may not be available to the pathologist. Alternatively, this checklist may not be applicable to some situations (e.g., group IIIA). If applicable, the appropriate stage group may be assigned by the pathologist.

__ Not applicable: ____________________
__ Cannot be assessed (explain): ____________________

Group I
__ Group IA Localized tumor, confined to site of origin, completely resected
__ Group IB Localized tumor, infiltrating beyond site of origin, completely resected

Group II
__ Group IIA Localized tumor, gross total resection, but with microscopic residual disease
__ Group IIB Locally extensive tumor (spread to regional lymph nodes), completely resected
__ Group IIC Locally extensive tumor (spread to regional lymph nodes), gross total resection, but microscopic residual disease

Group III
__ Group IIIA Localized or locally extensive tumor, gross residual disease after biopsy only
__ Group IIIB Localized or locally extensive tumor, gross residual disease after major resection (greater than 50% debulking)

Group IV
__ Group IV Any size primary tumor, with or without regional lymph node involvement, with distant metastases, without respect to surgical approach to primary tumor.

Modified Site, Size, Metastasis Staging for Rhabdomyosarcoma (for relevant stage) (Note H)

Staging is based on pretreatment tumor characteristics. Clinical information required to definitively assign stage (e.g., nodal status or distant metastatic disease) may not be available to the pathologist.

__ Not applicable: ____________________
__ Cannot be assessed (explain): ____________________
__ Stage I (requires all of the following to be true: Tumor involves favorable site (i.e., biliary tract / liver, orbit, head and neck [excluding parameningeal] or genitourinary site [excluding bladder / prostate]), and; Tumor metastatic to distant site not identified)
__ Stage II (requires all of the following to be true: Tumor involves unfavorable site (i.e., bladder / prostate, extremity, parameningeal or other site not mentioned in stage I), and; Tumor size less than or equal to 5 cm, and; Tumor involvement of lymph nodes not identified, and; Tumor metastatic to distant site not identified)
__ Stage III (requires that one of the following be true: Tumor involves unfavorable site, is less than or equal to 5 cm, and involves regional lymph nodes, but distant metastases are not identified, or; Tumor involves unfavorable site and is greater than 5 cm, with or without regional lymph node involvement, but distant metastases are not identified)

Stage III Findings
__ Tumor involves unfavorable site, is less than or equal to 5 cm, and involves regional lymph nodes, but distant metastases are not identified
__ Tumor involves unfavorable site and is greater than 5 cm, with or without regional lymph node involvement, but distant metastases are not identified
__ Stage IV (requires that distant metastases be present)
ADDITIONAL FINDINGS

+Additional Findings (specify) (Note I): _________________

SPECIAL STUDIES

Gene Fusion Studies (Note J)
___ Not performed
___ Results pending
___ No FOXO1 rearrangement
___ FOXO1 rearrangement present
   ___ Fusion partner not known
   ___ FOXO1-PAX3 gene rearrangement
   ___ FOXO1-PAX7 gene rearrangement
   ___ Other (e.g., PAX3-NCOA1 or other variant translocation) (specify): _________________

Method for Gene Fusion Studies
___ Not applicable (Gene Fusion Studies not performed)
___ Conventional karyotyping
___ Fluorescent in situ hybridization (FISH)
___ Reverse transcriptase polymerase chain reaction (RT-PCR)
___ Sequencing (specify type, if known): _________________
___ Other (specify): _________________
___ Not known

+Molecular Genetic Studies (Note K) (select all that apply)
___ Not performed
___ Pending
___ DICER1 mutation
___ MyoD1 L122R point mutation
___ VGLL2 / NCOA2 gene fusions (specify): _________________
___ EWSR1 / FUS-TFCP2 gene fusion (specify): _________________
___ Other (specify): _________________

+Method for Molecular Genetic Studies (select all that apply)
___ Fluorescent in situ hybridization (FISH)
___ Reverse transcriptase polymerase chain reaction (RT-PCR)
___ Sequencing (specify type, if known): _________________
___ Other (specify): _________________

COMMENTS

Comment(s): _________________
Explanatory Notes

A. Expert Consultation
Expert consultation is not required. This question has been added to annotate, if so desired, that the case has been sent out for consultation and thus items of the CAP protocol could not be completed pending expert consultation. Completion of the CAP protocol will then be performed following consultation.

B. Submission of Tissue
If feasible, a minimum of 100 mg of viable tumor should be snap-frozen for potential molecular studies.1 If tissue is limited, the pathologist can keep the frozen tissue aliquot used for frozen section (usually done to determine sample adequacy and viability) in a frozen state (-80°C or lower), with the proviso that routine examination of this tissue may be required if the tissue is otherwise inadequate. Molecular studies to evaluate fusion status, FISH or RT-PCR, may be performed on paraffin sections or frozen tissue. When material is scant, FISH can also be performed on touch preparations made from fresh material obtained at the time of biopsy.

References

C. Procedures
Core needle biopsies can obtain sufficient material for special studies and morphologic diagnosis, but sampling problems may limit tumor subtyping. Inadequate sampling with needle biopsies may be related to specimen size, necrosis, hemorrhage, crush artifact, and specimen adequacy.1 Open incisional biopsy consistently provides a larger sample of tissue and maximizes the opportunity for a specific pathologic diagnosis.2 Excisional biopsy may not include an adequate margin of normal tissue, even with an operative impression of total gross removal.2 For all types of resections, marking (inking followed by use of a mordant) and orientation of the specimen (prior to cutting) are mandatory for accurate pathologic evaluation.2

References

D. Histologic Type
The International Classification of Rhabdomyosarcoma classified childhood rhabdomyosarcoma (RMS) into prognostically useful histologic categories.1 However, studies show that FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma, and histologic classification is no longer the primary tool for determining prognosis and risk stratification.2,3 That notwithstanding, a consistent and appropriate designation of histologic subtype remains important due to its universal applications. The 5th edition of WHO Classification of Tumours of Soft Tissue and Bone defines the histologic classification of rhabdomyosarcoma in 4 categories: embryonal (including botryoid), alveolar, spindle cell/sclerosing, and pleomorphic subtypes.4 Pleomorphic RMS is exceedingly rare and not well characterized in the pediatric population; many of these cases can be considered RMS with diffuse anaplasia. In addition to these subtypes, recent studies have further characterized the clinicopathologic and molecular subtypes of
spindle cell rhabdomyosarcoma; however, to-date all biologic subtypes still fall within in the histologic category of spindle cell RMS in the WHO Classification. This pattern, as well as ectomesenchymoma (RMS with ganglion cell or neuroblastic differentiation) and other histologic patterns are discussed in more detail below. Finally, RMS, not otherwise specified (NOS), is reserved for cases where there is insufficient material for confident histologic classification.

Embryonal Rhabdomyosarcoma

Embryonal RMS (ERMS) includes the typical, dense and botryoid patterns of RMS. These patterns account for over one-half of all RMS. Embryonal RMS is composed of mesenchymal cells that show variable degrees of cytoplasmic skeletal muscle differentiation. They are moderately cellular, but in the typical pattern often contain both hypo- and hypercellular areas with a loose, myxoid stroma. Either of these components may predominate, particularly in limited biopsies. Sampling of uniformly hypercellular regions produces a dense pattern of embryonal RMS that may resemble solid alveolar RMS. The typical immunohistochemical staining pattern of ERMS, with myogenin (myf4) staining most often seen in less than half of embryonal RMS nuclei, absent AP2 beta staining and strong diffuse expression of HMGA2 support this diagnosis. Testing for PAX-FOXO1 translocations may also assist in making this distinction.

In embryonal RMS, tumor cells may be rounded, stellate, or spindle-shaped. Nuclei are generally small with a light chromatin pattern and inconspicuous nucleoli, although occasionally large central nucleoli may be seen. They typically have more irregular or spindled outlines than those of alveolar RMS. Many tumor cells contain generous amounts of eosinophilic cytoplasm, a feature of rhabdomyoblastic differentiation. Cells with elongated tails of cytoplasm (“tadpole cells”) and cells with cytoplasm in the shape of a ribbon or “strap” are helpful in the light-microscopic diagnosis. Cross-striations can be seen in less than one-half of the cases and are not a prerequisite for diagnosis. The dense pattern of embryonal RMS shows similar cytologic features, although rhabdomyoblastic differentiation is minimal. Adjacent to an epithelial surface, embryonal RMS shows a botryoid pattern, particularly in the bladder, vagina, nasal cavity and sinuses, and biliary tract. These botryoid variants demonstrate a cambium layer (condensed layer of rhabdomyoblasts) underlying an intact epithelium. A subset of embryonal RMS are associated with either sporadic or germline Dicer1 mutations. These Dicer1 mutated embryonal RMS are most commonly located in the uterine corpus or uterine cervix, although they are also described less frequently in other locations including the ovary, fallopian tube, or intracranial sites. Histologically, Dicer1 mutated embryonal RMS often contain heterologous elements to include nodules of cartilage, osteoid, or other non-rhabdomyomatous components; these tumors are often histologically similar to that seen in pleuropulmonary blastoma (PPB). Rarely, embryonal RMS may be predominantly epithelioid (or rhaboid-like).

The differential diagnosis of embryonal RMS includes the sclerosing and spindle cell variants of RMS, as well as the solid pattern of alveolar RMS. Embryonal RMS is often quite heterogeneous, and small foci of a spindled or sclerosing pattern are commonly seen, particularly in primary resections of large paratesticular or retroperitoneal masses. A dominant (at least 80%) spindled or sclerosing pattern is required for diagnosis of this RMS subtype. Ectomesenchymoma (discussed below) typically has embryonal RMS along with a neuroblastic or ganglion cell component. Undifferentiated embryonal sarcoma of the liver has some morphologic and phenotypic overlap, but it generally does not express Myod1 (myf3) or myogenin by immunohistochemistry and contains characteristic cytoplasmic hyaline globules. Embryonal RMS-like differentiation is a common component of the multipatterned pediatric lung tumor pleuropulmonary blastoma. Occasional Wilms tumors show marked skeletal muscle differentiation, particularly after chemotherapy, and may even have a cambium layer in tumors abutting the renal pelvis.
Well-differentiated embryonal RMS can also have some morphologic overlap with fetal rhabdomyoma. The finding of increased mitoses (>15 per 50 high-power fields), marked hypercellularity, a “cambium layer,” and atypical nuclear features are more characteristic of RMS. Giant cell tumors of tendon sheath may lack giant cells, contain cells with eosinophilic cytoplasm, and show desmin positivity; however, they are strongly CD68 positive and myogenin negative. Pseudosarcomatous fibroepithelial polyps of the lower female genital tract are particularly treacherous and should be considered in botryoid lesions occurring in adolescents and adults, particularly during pregnancy. These hypercellular lesions contain pleomorphic cells with a variable mitotic rate and frequently express desmin; however, they lack a cambium layer or striated cells and do not express myogenin.

Alveolar Rhabdomyosarcoma
Alveolar RMS is histologic pattern composed of malignant small rounded cells that are typically discohesive with a tendency to attach to and line up along thin fibrous septa. The tumor cells have some variation in size. Tumor cell nuclei are round and lymphocyte-like with coarse chromatin and one or more indistinct nucleoli. Tumor cells may show a thin rim of eosinophilic cytoplasm. Morphologic evidence of rhabdomyoblastic differentiation including strap cells or cells with cross-striations is often lacking, although multinucleate myoblasts may be seen. It is important to recognize the “solid variant,” in which the tumor cells grow in solid masses of closely aggregated cells. Classification as alveolar RMS is based on histologic features, as approximately 15 to 20% of all alveolar RMS will lack FOXO1 fusion genes.

The differential diagnosis of alveolar RMS includes the panoply of malignant small round cell neoplasms, particularly Ewing sarcoma, poorly differentiated or undifferentiated neuroblastoma, desmoplastic small round cell tumor, poorly differentiated monophasic synovial sarcoma, and lymphoma. A panel of immunohistochemical stains including myogenin, desmin, MYOD1, cytokeratin, CD99, WT1, synaptophysin, chromogranin, and leukocyte common antigen (CD45) will distinguish alveolar RMS from these other entities, but unexpected staining with antigens such as cytokeratin may occur. In contrast to dense ERMS, ARMS shows strong diffuse staining with myogenin (typically >80%) and AP2beta, with weak to absent HMGA2. Molecular studies show PAX3- and PAX7-FOXO1 fusion gene products occur in approximately 80-85% of alveolar RMS cases. Molecular testing is required for risk stratification in all alveolar RMS cases.

Spindle Cell/Sclerosing Rhabdomyosarcoma
In the 5th edition of *WHO Classification of Tumours of Soft Tissue and Bone*, spindle cell and sclerosing RMS are considered in the same diagnostic category. Spindle cell / sclerosing RMS is uncommon, accounting for 3% to 10% of all cases of RMS. Spindle cell/sclerosing rhabdomyosarcoma includes three distinct genetic subtypes. First, in infants, spindle cell RMS is often associated with recurrent non-FOXO1 gene fusions involving VGLL2 or NCOA2; these are of unclear prognosis. Initial studies demonstrated these tumors to have a favorable prognosis. However, a recent study showed a subset of tumors with a more aggressive biology including recurrence, metastasis and death from disease, to include late events. This remains an evolving area with, to-date, an uncertain overall prognosis. Second, MYOD1 mutated spindle cell/sclerosing RMS occurs more frequently in adolescents and adults. These tumors are more common in the head and neck region (particularly parameningeal) and are associated with a poor prognosis, including a recurrence and metastasis rate of 40%-50%. One study of patients with MYOD1 mutated RMS showed 68% died of disease. Third, recent series describe an intraosseous spindle cell RMS involving fusions of the *TFCP2* gene to either *EWSR1* or *FUS* genes, which also demonstrate immunoreactivity to keratins and ALK. These tumors are also associated with a poor outcome, although there are few cases published to date.
Of note, in children, a subset of spindle cell RMS located in the paratesticular region, do not have known recurrent genetic aberrations. Spindle cell RMS account for 26.7% of RMS in the paratesticular site, the remainder mostly being typical embryonal RMS; these spindle cell RMS may also represent a spindled variant of embryonal RMS. The 5-year survival for patients with spindle cell RMS in the paratesticular location is excellent.

Histologically, spindle cell / sclerosing RMS is somewhat variable. The spindle cell morphologic pattern is that of ovoid to fusiform spindle cells, arranged in fascicles or bundles, sometimes with a herringbone like growth pattern. Spindle cell RMS of infancy can have a more myoid appearance which can resemble a smooth muscle tumor. Some cases may contain rhabdomyoblastic differentiation; however, this tends to not be as pronounced as typically observed in embryonal RMS. Infantile spindle cell RMS and the spindled pattern of ERMS are exclusively spindled, without regions of sclerosis. In contrast, spindle or sclerosing patterns may be seen in MYOD1 mutated tumors. Sclerosing RMS is characterized by a dense hyalinizing collagenous matrix with rounded or spindle-shaped tumor cells arranged in small nests, single-file rows, and pseudovascular, microalveolar profiles. Spindle cell/sclerosing RMS may have only focal positivity for desmin and myogenin (myf4) but typically strongly expresses MYOD1 (myf3).

The primary differential diagnosis of spindle cell RMS includes embryonal RMS NOS, leiomyosarcoma, fibrosarcoma, undifferentiated spindle cell sarcoma, and the more bland entities, rhabdomyoma, leiomyoma, and nodular fasciitis. In general, smooth muscle neoplasms are uncommon in childhood and adolescence. The presence of specific skeletal muscle antigens (e.g. myoglobin, MYOD1, myogenin) and the ultrastructural presence of skeletal myofilaments or sarcomeric structures help in distinguishing spindle cell RMS from leiomyosarcoma, fibrosarcoma, and undifferentiated spindle cell sarcoma. The histologic differential for the sclerosing pattern RMS includes sclerosing epithelioid fibrosarcoma, infiltrating carcinoma, osteosarcoma, and angiosarcoma.

**Ectomesenchymoma**

Ectomesenchymoma is a rare malignant tumor that generally consists of an RMS component (embryonal greater than alveolar) and a ganglionic and/or neuroblastic component. The name originates from the belief that these tumors arise from pluripotent migrating neural crest cells or "ectomesenchyme." They have a similar age, sex, and site distribution and outcome to embryonal RMS and are treated with RMS-based therapy. Ectomesenchymomas may be further subclassified based on the subtype of RMS seen.

**Other**

In very rare occasions, an alveolar RMS pattern can be seen in a tumor that would otherwise be classified as embryonal RMS. These mixed alveolar and embryonal tumors resemble “collision” tumors, with differential myogenin expression between alveolar and embryonal components. These tumors may be fusion positive (most frequently PAX7-FOXO1) or fusion negative, although when tested separately each component shows the same genetic profile.

Posttreatment RMS may show extensive cytodifferentiation mimicking a highly differentiated embryonal RMS (see Note G).

**RMS, Not Otherwise Specified**

RMS, NOS, is reserved for cases in which a diagnosis of RMS can be made based on immunohistochemistry, but the case cannot be confidently further classified due to extensive necrosis, crush, or other aspect of the specimen that limits histologic interpretation.
Immunohistochemistry
In cases where histological diagnosis of rhabdomyosarcoma is difficult, immunostaining with monoclonal antibodies against the intranuclear myogenic transcription factors MYOD1 and myogenin, and the cytoplasmic intermediate filament desmin is suggested. Nearly all RMS tumors are positive for desmin, myogenin (nuclear), and MyoD1 (nuclear). On occasion, anti-myogenin reacts with other spindle cell neoplasms, and rare RMS cases may be myogenin negative and desmin positive. Of note, desmin expression is frequent in certain round cell tumors, such as blastemal Wilms tumor, tenosynovial giant cell tumor, and desmoplastic small round cell tumor. Myogenin is more specific but may occur in rare lesions such as melanotic neuroectodermal tumor of infancy, as well as, any lesion capable of skeletal myogenesis such as Wilms tumor, teratoma, pleuropulmonary blastoma, or malignant Triton tumor (malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation). Caution should also be taken when interpreting myogenin reactivity in tumors that interface with normal skeletal muscle, as injured muscle fibers can express myogenin.

References
10. McCluggage WG, Apellaniz-Ruiz M, Chong AL, Hanley KZ, Velázquez Vega JE, McVeigh TP, Foulkes WD. Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms
CAP Approved

Rhabdomyosarcoma_4.1.1.1.REL_CAPCP


E. Anaplasia

Anaplasia is found in up to 16% of RMS and may be found in any histologic subtype. Anaplastic tumors are defined as having large, lobate, hyperchromatic nuclei (at least 3 times the size of neighboring nuclei) or atypical (obvious, multipolar) mitotic figures.
Anaplasia is further described based on distribution of the anaplastic cells: focal (group I) anaplasia, which consists of a single or a few cells, scattered amongst nonanaplastic cells; or diffuse (group II), in which clusters or sheets of anaplastic cells are evident. These features should be visible at low power (10X objective) to avoid confusing it with “nuclear unrest,” characterized by mild degrees of hyperchromatism and nuclear atypia that do not qualify as 3X enlargement, do not contain atypical mitoses. Care must also be taken to distinguish anaplasia from the changes of myogenic differentiation, ie, multinucleation, overlapping nuclei, and nuclear atypia. However, this can be avoided by identifying atypical, multipolar mitoses and using caution in cells with abundant cytoplasm. Anaplasia is more common in tumors arising at favorable sites, and in stage 1 and clinical group I and II tumors. A recent large study showed no difference in failure-free or overall survival in patients with RMS having no anaplasia, focal anaplasia or diffuse anaplasia, and anaplasia was not an independent adverse prognostic factor. Anaplasia is associated with TP53 mutations, and 69% of tumors with TP53 mutations showed histologic anaplasia in this same series. Because of the correlation between anaplastic embryonal RMS and TP53 mutations (both tumor and germline), screening for germline TP53 mutations may be indicated in these patients.

References

F. Treatment Effect
Posttreatment (chemotherapy or radiation), RMS may undergo extensive cytodifferentiation. This appears to be more common in embryonal RMS than alveolar RMS. Studies suggest that tumor cells that have undergone maturation have little, if any, malignant potential. The significance of cytodifferentiation on outcome in RMS is not clear but may be a predictor of improved survival.

References
G. Margins
The extent of resection (ie, gross residual disease versus complete resection) has the strongest influence on local control of malignancy.\textsuperscript{1,2} The definition of what constitutes a sufficiently “wide” margin of normal tissue in the management of RMS has evolved over time from resection of the whole muscle to resection with a 2-3 cm margin.

References

H. Clinical Grouping and Modified “TNM” Staging
The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging systems currently do not apply to pediatric RMS. The Intergroup Rhabdomyosarcoma Study Postsurgical Clinical Grouping System is recommended by this protocol. The Clinical Grouping System is a surgical-pathological grouping system. It categorizes patients into groups I-IV based on the extent of disease after initial surgical procedure(s) and prior to initiation of radiation therapy and/or systemic therapy. This includes consideration of the extent of the disease at the primary site as well as regional lymph node and distant metastatic involvement.\textsuperscript{1}

Also provided in this protocol is the “TNM” staging system modified for use with rhabdomyosarcoma. This system is a clinical staging system. The TNM staging system categorizes patients into stages 1-4 based on physical exam and imaging findings prior to any therapeutic intervention (i.e. prior to surgery, radiation or systemic therapy). It considers primary site, tumor size, and regional lymph nodes and distant metastatic involvement. This modified staging system is predictive of outcome in rhabdomyosarcoma.\textsuperscript{1,2,3}

Clinical classification usually is carried out by the referring physician before treatment, during initial evaluation of the patient or when pathologic classification is not possible.

References

I. Relevant History
Relevant historical factors include any previous therapy, family history of malignancy, and the presence of congenital anomalies. If preoperative therapy has been given, assessment may be limited to the estimate of viable and necrotic RMS.\textsuperscript{1} The tumor may also show extreme cytodifferentiation and nuclear pleomorphism. These factors may preclude accurate subtyping of the RMS. There is a specific concern for increased risk of a familial cancer when the specific diagnosis of embryonal RMS or other soft tissue sarcoma is made within the first 2 years of life, especially in a male
Such syndromes include Li-Fraumeni syndrome, basal cell nevus syndrome, neurofibromatosis, and pleuropulmonary blastoma syndrome (pleuropulmonary blastoma plus malignancies associated with germline DICER1 mutations). Agenetic predisposition to cancer is thought to be present in 7%-33% of children with soft tissue sarcomas.

Rhabdomyosarcoma is specifically associated with a variety of congenital anomalies. These include congenital anomalies of the central nervous system, genitourinary tract, gastrointestinal tract, and cardiovascular system.

References

J. Fusion Status
The presence of a t(1;13) (resulting in a PAX7-FOXO1 (FKHR) gene fusion) or a t(2;13) (PAX3-FOXO1 gene fusion) is strongly correlated with the alveolar subtype of rhabdomyosarcoma. These translocations may be found in as many as 85% of alveolar RMS cases, while embryonal RMS cases lack evidence of these gene fusions (with rare exceptions). Some tumors with alveolar histology lack a demonstrable PAX fusion. By gene expression profiling, they do not cluster with PAX fusion-positive tumors and have a genetic signature that more closely resembles embryonal RMS. Recent studies have confirmed that the presence of a PAX-FOXO1 fusion transcript drives outcome in children with rhabdomyosarcoma. Accordingly, future cooperative group studies conducted by both the Children’s Oncology Group and European Pediatric Soft Tissue Sarcoma Group will use FOXO1 fusion status rather than alveolar histology to assign risk stratification and treatment for patients with RMS. Fusion status is therefore a required element for all patients with alveolar rhabdomyosarcoma. In contrast, embryonal and non-alveolar patterns of rhabdomyosarcoma are nearly always FOXO1 fusion negative and testing is not required. However, fusion studies can be extremely useful in cases with limited or questionable material, those in which histologic classification is difficult or those with unusual clinical characteristics (e.g., embryonal subtype arising in an extremity). PAX-FOXO1 gene fusions have also been described in mixed alveolar and embryonal rhabdomyosarcoma and ecmesenchymoma with an alveolar RMS component.
Of fusion-positive RMS cases, approximately 30% are positive for PAX7-FOXO1, and the remaining 70% are positive for PAX3-FOXO1. If RT-PCR using PAX3- or PAX7-specific probes is not used to determine fusion status, amplification of FOXO1 on break-apart FISH studies can act as a surrogate marker of PAX7-FOXO1 fusion status. Studies suggest that patients with alveolar RMS expressing the PAX3-FOXO1 gene product have a lower event-free survival than PAX7-FOXO1-positive alveolar RMS, but the significance of the translocations must still be elucidated. Some data indicate that when gene fusion status is compared in patients with metastatic disease at diagnosis, a striking difference in outcome is seen between PAX7-FOXO1 and PAX3-FOXO1 (estimated 4-year overall survival of 75% for PAX7-FOXO1 and 8% for PAX3-FOXO1; P=.002).

Although rare, several variant fusion transcripts have been described in alveolar RMS. Most include fusion of PAX3 with an alternate partner, such as NCOA1, NCOA2, or FOXO4. Less often FOXO1 is preserved and fused with another partner, such as FGFR1. Due to the low incidence of these variant fusion transcripts, the prognostic significance is unknown. Some evidence suggests different fusion transcripts may confer different prognostic effects, but until more is known these tumors are treated under fusion-positive RMS protocols.

References
K. Molecular Genetic Studies
As noted in the histologic types section (Note C), some molecular alterations may be associated with particular RMS subtypes. Additionally, some alterations may have prognostic or germline implications. DICER1 mutations are associated with a subset of embryonal RMS and may be somatic or germline; identification of a DICER1 mutation in an embryonal RMS tumor warrants additional exploration for the possibility of DICER1 syndrome/PPB-tumor predisposition syndrome (germline mutations associated with PPB, ERMS, cystic nephroma, sex cord stromal tumors, pineal blastoma, among other tumors).1 In spindle cell / sclerosing RMS, MYOD1 L122R point mutations are of prognostic significance, with those tumors containing this alterations demonstrating a more aggressive biology.2 Both DICER1 and MYOD1 alterations are point mutations and the sensitivity for detecting these mutations in next-generation sequencing panels designed to detect RNA fusions may be variable; detection of these mutations using targeted DNA sequencing may be considered as an alternative. In spindle cell RMS in infants, detection of a VGLL2 or NCOA2 gene fusion may be helpful in diagnosis as well as predictive of a favorable prognosis. Intraosseous spindle cell RMS is an evolving diagnostic area; identification of either a EWSR1-TFCP2 or FUS-TFCP2 fusion may aid in the diagnosis of this rare subtype.3,4,5

References